U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C68H105N11O15
Molecular Weight 1316.626
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SGD-1006

SMILES

[H][C@]([C@@H](C)CC)([C@@H](CC(=O)N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C2=CC=CC=C2)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN4C(=O)C=CC4=O)C(C)C)C=C3)C(C)C

InChI

InChIKey=NLMBVBUNULOTNS-HOKPPMCLSA-N
InChI=1S/C68H105N11O15/c1-15-43(8)59(51(92-13)38-55(83)78-37-23-27-50(78)61(93-14)44(9)62(85)71-45(10)60(84)47-24-18-16-19-25-47)76(11)66(89)57(41(4)5)75-65(88)58(42(6)7)77(12)68(91)94-39-46-29-31-48(32-30-46)72-63(86)49(26-22-35-70-67(69)90)73-64(87)56(40(2)3)74-52(80)28-20-17-21-36-79-53(81)33-34-54(79)82/h16,18-19,24-25,29-34,40-45,49-51,56-61,84H,15,17,20-23,26-28,35-39H2,1-14H3,(H,71,85)(H,72,86)(H,73,87)(H,74,80)(H,75,88)(H3,69,70,90)/t43-,44+,45+,49-,50-,51+,56-,57-,58-,59-,60+,61+/m0/s1

HIDE SMILES / InChI
VcMMAE (valine-citrulline-MMAE) is a drug-linker conjugate for antibody-drug conjugates (ADC) with potent antitumor activity by using the anti-mitotic and cytotoxic drug, monomethyl auristatin E (MMAE). MMAE is linked via the lysosomally cleavable dipeptide, valine-citrulline (vc), which can be specifically hydrolyzed by endosomal proteases, such as cathepsin B. ADCs developed using the valine-citrulline-MMAE (vc-MMAE) platform are studied for the treatment of different types of cancers.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P07858
Gene ID: 1508.0
Gene Symbol: CTSB
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.
2016
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
2017 Dec

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
It was evaluated the cytotoxic effect of the FGF1V–vcMMAE conjugate on FGFR-expressing cells, including a model human fibroblast cell line, BJ. To test whether the cytotoxic effect is specific to FGFR-expressing cells, we employed a model system of U2OS and U2OS FGFR1 cells (stably transfected with the FGFR1) in which otherwise identical osteosarcoma cells lacking and expressing FGFRs can be compared. All the cell lines were treated with increasing concentrations (1*10(-9) – 1*10(-5) M) of the conjugate, FGF1V, or vcMMAE for 96 hours, and then their viability was assessed by the alamarBlue assay or counting in trypan Blue stain. As the maximum cytotoxic effect of both vcMMAE and FGF1V–MMAE was reached after 72–96 hours, the cytotoxicity assessment was performed after 96 hours of treatment.
Name Type Language
SGD-1006
Code English
VC-MMAE
Common Name English
VCMMAE
Common Name English
VEDOTIN PARENT
Common Name English
MALEIMIDOCAPROYL-VALINE-CITRULLINE-P-AMINOBENZYLOXYCARBONYL-MONOMETHYLAURISTATIN E
Common Name English
MC-VC-PAB-MMAE
Common Name English
Code System Code Type Description
CAS
646502-53-6
Created by admin on Sat Dec 16 05:44:33 GMT 2023 , Edited by admin on Sat Dec 16 05:44:33 GMT 2023
PRIMARY
PUBCHEM
46944733
Created by admin on Sat Dec 16 05:44:33 GMT 2023 , Edited by admin on Sat Dec 16 05:44:33 GMT 2023
PRIMARY
FDA UNII
026S2O80A8
Created by admin on Sat Dec 16 05:44:33 GMT 2023 , Edited by admin on Sat Dec 16 05:44:33 GMT 2023
PRIMARY